Stock listing
OTC:MHTX Manhattan Scientifics, Inc. Stock
Follow Manhattan Scientifics, Inc. into a list and get an email when it puts out news.
- Ticker
- OTC:MHTX
- Asset type
- Stock
- Exchange
- OTC
- Currency
- USD
Manhattan Scientifics, Inc. on 6ix
- News releases
- 42 in all · newest Jun 29, 2023 · oldest 2014
Events
| Quarter | Results |
|---|
| Quarter to Sep 30, 2024 | Nov 27, 2024 |
|---|
| Q2 2024 | Aug 19, 2024 · Before open |
|---|
| Q1 2024 | May 15, 2024 · After close |
|---|
| Q4 2023 | Mar 27, 2024 · After close |
|---|
| Q3 2023 | Nov 20, 2023 · Before open |
|---|
| Q2 2023 | Aug 21, 2023 · After close |
|---|
| Q1 2023 | May 22, 2023 · After close |
|---|
| Q4 2022 | Mar 1, 2023 |
|---|
| Q3 2022 | Nov 14, 2022 |
|---|
| Q2 2022 | Aug 31, 2022 |
|---|
All 16 quarters
| Quarter | Results |
|---|
| Q1 2022 | May 17, 2022 |
|---|
| Q4 2021 | Mar 2, 2022 |
|---|
| Q3 2021 | Dec 1, 2021 |
|---|
| Q2 2021 | Sep 1, 2021 |
|---|
| Q1 2021 | May 18, 2021 |
|---|
| Q4 2020 | Mar 3, 2021 |
|---|
Open Events
Financials
Annual, in USD
Income statement
| Line | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 |
|---|
| Revenue | 0 | 50.0K | 50.0K | 50.0K | 97.0K | 0 | 142.0K | 150.0K | 64.0K | 642.0K |
|---|
| Cost of revenue | 1.00K | 3.00K | 2.00K | 725.0K | 0 | 7.00K | 189.0K | 43.0K | 3.99M | 3.92M |
|---|
| Gross profit | -1.00K | 50.0K | 50.0K | 50.0K | 97.0K | -7.00K | -47.0K | 107.0K | 64.0K | 642.0K |
|---|
| Research and development | 10.0K | 11.0K | 10.0K | 11.0K | 8.00K | 52.0K | 175.0K | 3.33M | 2.94M | 1.86M |
|---|
| Selling, general and administrative | 693.0K | 718.0K | 727.0K | 714.0K | 1.11M | 1.39M | 2.06M | 3.20M | 3.38M | 2.26M |
|---|
| Operating income | -703.0K | -679.0K | -687.0K | -675.0K | -1.02M | -1.45M | -2.28M | -6.38M | -6.25M | -3.47M |
|---|
| Depreciation and amortization | 1.00K | 3.00K | 2.00K | 2.00K | 2.00K | 622.0K | 857.0K | 995.0K | 793.0K | 202.0K |
|---|
| EBITDA | -702.0K | -676.0K | -685.0K | -673.0K | -1.02M | -826.0K | -1.42M | -5.39M | -5.46M | -3.27M |
|---|
| Interest expense | 0 | 21.0K | 26.0K | 25.0K | 5.00K | 0 | 0 | 488.0K | 675.0K | 330.0K |
|---|
| Income before tax | -1.17M | -2.73M | -3.64M | 4.31M | -1.22M | -8.33M | 1.55M | -6.11M | 8.01M | -3.81M |
|---|
| Income tax | -1.17M | 2.03M | 26.0K | 25.0K | 5.00K | -6.89M | 1.00K | 488.0K | 675.0K | 0 |
|---|
| Net income | -1.17M | -2.73M | -3.64M | 4.31M | -1.22M | -8.33M | 1.55M | -6.11M | 8.01M | -3.81M |
|---|
| Earnings per share, basic | -0.00 | -0.00 | -0.01 | 0.01 | -0.00 | -0.02 | 0.00 | -0.01 | 0.01 | -0.01 |
|---|
Balance sheet
| Line | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 |
|---|
| Cash and equivalents | 67.0K | 175.0K | 232.0K | 353.0K | 261.0K | 87.0K | 269.0K | 1.07M | 5.36M | 2.53M |
|---|
| Short-term investments | | | | 5.88M | | 0 | 0 | 0 | 0 | |
|---|
| Receivables | | | 300.0K | 300.0K | 300.0K | | | 44.0K | | |
|---|
| Inventory | | | -300.0K | -300.0K | -300.0K | 0 | 0 | 0 | 0 | |
|---|
| Current assets | 69.0K | 189.0K | 547.0K | 665.0K | 574.0K | 98.0K | 278.0K | 1.11M | 5.36M | 2.53M |
|---|
| Property, plant and equipment | | | 4.00K | 6.00K | 4.00K | 6.00K | 8.00K | 165.0K | 291.0K | 144.0K |
|---|
| Goodwill | | | | | | 0 | 0 | 0 | 0 | |
|---|
| Total assets | 316.0K | 1.03M | 3.45M | 6.85M | 2.23M | 2.66M | 10.8M | 7.63M | 12.9M | 3.63M |
|---|
| Accounts payable | 133.0K | 119.0K | 102.0K | 159.0K | 234.0K | 221.0K | 209.0K | 472.0K | 829.0K | 426.0K |
|---|
| Current liabilities | 2.12M | 1.67M | 1.36M | 1.01M | 2.09M | 1.75M | 1.63M | 1.71M | 1.29M | 1.79M |
|---|
| Long-term debt | | | | 104.0K | 78.0K | 0 | 0 | 2.14M | 1.93M | 1.62M |
|---|
| Total debt | 60.0K | 110.0K | 130.0K | 104.0K | 78.0K | | | 2.41M | 2.38M | 2.96M |
|---|
| Total liabilities | 2.12M | 2.73M | 2.42M | 2.17M | 3.23M | 2.81M | 2.69M | 4.91M | 4.28M | 4.46M |
|---|
| Shareholders' equity | -1.80M | -1.70M | 1.03M | 4.67M | -1.00M | -150.0K | 8.16M | 2.72M | 8.59M | -832.0K |
|---|
| Shares outstanding | 559.3M | 559.3M | 559.3M | 593.1M | 549.4M | 533.8M | 533.8M | 534.7M | 593.4M | 485.6M |
|---|
Cash flow
| Line | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 |
|---|
| Cash from operations | -190.0K | -349.0K | -421.0K | -388.0K | -316.0K | -682.0K | -791.0K | -4.56M | 3.42M | -2.54M |
|---|
| Capital spending | 0 | 0 | 0 | -4.00K | -4.00K | -4.00K | -8.00K | -13.0K | -255.0K | -36.0K |
|---|
| Free cash flow | -190.0K | -349.0K | -421.0K | -392.0K | -316.0K | -682.0K | -799.0K | -4.57M | 3.16M | -2.57M |
|---|
| Cash from investing | 102.0K | 332.0K | 300.0K | 480.0K | 340.0K | 500.0K | -8.00K | -13.0K | -255.0K | -36.0K |
|---|
| Cash from financing | -20.0K | -40.0K | 0 | 24.0K | 150.0K | 150.0K | 150.0K | 275.0K | -324.0K | 4.52M |
|---|
| Dividends paid | | | | | | 0 | 0 | 0 | 0 | |
|---|
| Share buybacks | | | | | | 0 | 0 | 0 | -330.0K | 3.52M |
|---|
| Change in cash | -108.0K | -57.0K | -121.0K | 92.0K | 174.0K | -182.0K | -799.0K | -4.30M | 2.84M | 1.95M |
|---|
Open Financials
Cap table
Built by 6ix from Manhattan Scientifics, Inc.’s releases
- Common shares
- 559,281,064
- Fully diluted
- 559,281,064
Fully diluted
| Line | Shares |
|---|
| Common shares | 559,281,064 |
|---|
Share count over time
| Count | Shares |
|---|
| Nov 22, 2026 | 559,281,064 |
|---|
Open Cap table
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|
| Marvin Maslow | Chief Executive Officer · Aug 17, 2007 – Aug 17, 2007 · Past |
|---|
| Chris Theoharis | Treasurer, Director · Oct 11, 2007 – Jun 30, 2016 · Past |
|---|
| Emmanuel Tsoupanarias | CEO and Chairman of the Board, Director · Jun 30, 2014 – Jun 30, 2014 · Past |
|---|
| Leonard Friedman | Secretary, Director · Jun 30, 2014 – Jun 30, 2016 · Past |
|---|
| Photios Frank Georgiou | Director · Oct 11, 2007 – Jun 30, 2016 · Past |
|---|
Open People
Log in to ask 6ix AI your own questions about Manhattan Scientifics, Inc.